The primary endpoint was the the evaluation of safety in terms of rate of SAEs during the first year since the introduction of Inflectra/CT-P13* (infliximab) for the overall population.
Breakdown of SAEs experienced by the overall population.1
Adapted from Fliorino G. et al. 2017.
Learn about the safety profile of Inflectra in patients with Crohn’s disease
Learn about the dosing and administration of Inflectra in patients with Crohn’s disease
GONCZI L et al
PROSIT-BIO study design
Induction & Maintenance
Inflammatory bowel disease
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020